Author:
Ramírez-Toscano Yenisei,Torres-Ibarra Leticia,Carnalla Martha,Basto-Abreu Ana,Vidaña-Perez Dèsirée,Colchero M. Arantxa,Bautista-Arredondo Sergio,Saydah Sharon,Barrientos-Gutiérrez Tonatiuh
Abstract
Abstract
Background
There are limited population-representative data that describe the potential burden of Post-COVID conditions (PCC) in Mexico. We estimated the prevalence of PCC overall and by sociodemographic characteristics among a representative sample of adults previously diagnosed with COVID-19 in Mexico. We additionally, characterized the PCC symptoms, and estimated the association between diagnosed type-2 diabetes and hypertension with PCC.
Methods
We used data from the 2021 National Health and Nutrition Survey in Mexico, a nationally and regionally representative survey, from August 1st to October 31st, 2021. Using the WHO definition, we estimated the prevalence of PCC by sociodemographics and prevalence of PCC symptoms. We fit multivariable log-binomial regression models to estimate the associations.
Results
The prevalence of PCC was 37.0%. The most common persistent symptoms were fatigue (56.8%), myalgia or arthralgia (47.5%), respiratory distress and dyspnea (42.7%), headache (34.0%), and cough (25.7%). The prevalence was higher in older people, women, and individuals with low socioeconomic status. There was no significant association between hypertension and PCC or diabetes and PCC prevalence.
Conclusions
About one-third of the adult Mexican population who had COVID-19 in 2021 had Post-COVID conditions. Our population-based estimates can help assess potential priorities for PCC-related health services, which is critical in light of our weak health system and limited funding.
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601–15.
2. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102–7.
3. National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the long- term effects of COVID-19. 2022. https://www.nice.org.uk/guidance/ng188. Accessed 15 Jun 2022.
4. Centers for Disease Control and Prevention (CDC). Post-COVID Conditions: Information for Healthcare Providers. 2022. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html. Accessed 24 Apr 2023.
5. Office for National Statistics (ONS). Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. 2023. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/2february2023. Accessed 11 Apr 2023.